Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHC Acadia Healthcare	$22.96 +1.5%	$21.99	$17.13 ▼ $82.40	$2.12B	0.88	2.20 million shs	2.74 million shs
BLTE Belite Bio	$63.03 -2.3%	$63.42	$43.70 ▼ $86.53	$2.01B	-1.49	43,602 shs	17,203 shs
LCAP Lionheart Acquisition Co. II	$28.06 +0.5%	$10.38	$8.94 ▼ $11.70	$517.83M	0.08	102,067 shs	2,905 shs
MESO Mesoblast	$13.83 -13.3%	$13.78	$6.00 ▼ $22.00	$1.77B	2.4	272,758 shs	457,739 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHC Acadia Healthcare	+1.98%	+5.60%	+1.62%	-0.66%	-71.39%
BLTE Belite Bio	+0.48%	-1.06%	+1.45%	-1.51%	+32.00%
LCAP Lionheart Acquisition Co. II	+0.52%	+1.29%	+1.42%	+8.53%	+10,668.72%
MESO Mesoblast	-1.05%	+5.14%	+0.06%	+50.33%	+150.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHC Acadia Healthcare	4.6942 of 5 stars	4.3	2.0	0.0	5.0	1.8	0.0	2.5
BLTE Belite Bio	2.9577 of 5 stars	3.5	4.0	0.0	0.0	3.3	0.8	0.6
LCAP Lionheart Acquisition Co. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	2.9665 of 5 stars	3.6	4.0	0.0	0.0	3.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHC Acadia Healthcare	2.69	Moderate Buy	$40.77	77.58% Upside
BLTE Belite Bio	3.00	Buy	$96.67	53.37% Upside
LCAP Lionheart Acquisition Co. II	0.00	N/A	N/A	N/A
MESO Mesoblast	3.20	Buy	$18.00	30.15% Upside

Current Analyst Ratings Breakdown

Latest LCAP, ACHC, BLTE, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ACHC Acadia Healthcare	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Outperform	$40.00 ➝ $26.00
8/13/2025	ACHC Acadia Healthcare	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$32.00 ➝ $22.00
8/13/2025	ACHC Acadia Healthcare	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$43.00 ➝ $28.00
8/7/2025	ACHC Acadia Healthcare	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ACHC Acadia Healthcare	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $31.00
8/7/2025	ACHC Acadia Healthcare	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $29.00
8/7/2025	ACHC Acadia Healthcare	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $20.00
8/5/2025	MESO Mesoblast	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/2/2025	ACHC Acadia Healthcare	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHC Acadia Healthcare	$3.15B	0.67	$5.10 per share	4.50	$33.33 per share	0.69
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.71 per share	N/A
LCAP Lionheart Acquisition Co. II	N/A	N/A	$1.36 per share	20.64	($2.85) per share	N/A
MESO Mesoblast	$5.90M	300.04	N/A	N/A	$4.21 per share	3.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHC Acadia Healthcare	$255.61M	$1.51	15.21	6.77	4.37	4.31%	8.34%	4.20%	10/29/2025 (Estimated)
BLTE Belite Bio	-$36.14M	-$1.55	N/A	N/A	N/A	N/A	-34.90%	-33.56%	11/11/2025 (Estimated)
LCAP Lionheart Acquisition Co. II	$3.21M	N/A	0.00	∞	N/A	N/A	-44.30%	1.39%	N/A
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest LCAP, ACHC, BLTE, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	BLTE Belite Bio	-$0.47	-$0.50	-$0.03	-$0.50	N/A	N/A
8/5/2025	Q2 2025	ACHC Acadia Healthcare	$0.71	$0.83	+$0.12	$0.33	$839.59 million	$869.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHC Acadia Healthcare	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LCAP Lionheart Acquisition Co. II	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHC Acadia Healthcare	0.73	1.32	1.32
BLTE Belite Bio	N/A	23.15	23.15
LCAP Lionheart Acquisition Co. II	N/A	0.05	0.05
MESO Mesoblast	0.22	0.96	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHC Acadia Healthcare	N/A
BLTE Belite Bio	0.53%
LCAP Lionheart Acquisition Co. II	N/A
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ACHC Acadia Healthcare	1.30%
BLTE Belite Bio	13.29%
LCAP Lionheart Acquisition Co. II	19.40%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHC Acadia Healthcare	25,500	92.35 million	91.15 million	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
LCAP Lionheart Acquisition Co. II	3	18.45 million	14.87 million	Not Optionable
MESO Mesoblast	80	128.00 million	103.93 million	Optionable

LCAP, ACHC, BLTE, and MESO Headlines

Recent News About These Companies

Mesoblast Full Year 2025 Earnings: Misses Expectations

2 hours ago | finance.yahoo.com

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

August 28 at 8:24 PM | globenewswire.com

Examining the Future: Mesoblast's Earnings Outlook

August 27 at 12:55 AM | benzinga.com

Examining the Future: Mesoblast's Earnings Outlook

August 27 at 12:55 AM | benzinga.com

Mesoblast (MESO) Expected to Announce Quarterly Earnings on Wednesday

August 25, 2025 | americanbankingnews.com

Mesoblast (MESO) to Release Quarterly Earnings on Wednesday

August 21, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

August 16, 2025 | marketbeat.com

MESO | Mesoblast Ltd. ADR Annual Income Statement | MarketWatch

August 14, 2025 | marketwatch.com

Ulcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline | DelveInsight

August 13, 2025 | theglobeandmail.com

Mesoblast Limited (NASDAQ:MESO) Given Average Rating of "Buy" by Brokerages

August 9, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Rating Increased to Strong-Buy at Canaccord Genuity Group

August 9, 2025 | marketbeat.com

XY Capital Ltd Buys New Stake in Mesoblast Limited (NASDAQ:MESO)

August 9, 2025 | marketbeat.com

JPMorgan Acquires Substantial Stake in Mesoblast

July 23, 2025 | msn.com

Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know

July 22, 2025 | zacks.com

Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rally

July 21, 2025 | proactiveinvestors.com

Why Mesoblast shares can keep storming higher

July 21, 2025 | msn.com

Mesoblast stock soars after reporting first Ryoncil sales

July 19, 2025 | investing.com

Successful Commercial Launch of Ryoncil®

July 17, 2025 | globenewswire.com

Insider Stock Buying Reaches US$205.4m On Mesoblast

July 8, 2025 | finance.yahoo.com

Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)

July 7, 2025 | seekingalpha.com

Mesoblast Shares Surge on FDA Alignment

July 1, 2025 | sharecafe.com.auS

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCAP, ACHC, BLTE, and MESO Company Descriptions

Acadia Healthcare NASDAQ:ACHC

$22.96 +0.34 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$22.96 0.00 (0.00%)

As of 07:00 PM Eastern

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Belite Bio NASDAQ:BLTE

$63.03 -1.48 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$63.29 +0.26 (+0.41%)

As of 04:10 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lionheart Acquisition Co. II NASDAQ:LCAP

Lionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.

Mesoblast NASDAQ:MESO

$13.83 -2.12 (-13.29%)

Closing price 04:00 PM Eastern

Extended Trading

$13.83 0.00 (0.00%)

As of 06:01 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time